Biogen and Bio-Thera Reveal Tocilizumab Progress

Biosimilar Actemra Phase III Results Trigger $30m Payment Under April Deal

 
• By Dave Wallace

Biogen and Bio-Thera Solutions have reported positive results from a Phase III trial for their BAT1806 proposed biosimilar tocilizumab rival to Actemra. The milestone has triggered a $30m payment from Biogen under the pair’s development deal.

Tocilizumab Syringe Hand Glove
Biogen and Bio-Thera have announced Phase III results for their Actemra biosimilar • Source: Alamy

More from Biosimilars

More from Products